Skip to content

Author

Qing-Qing Ding

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Sacituzumab Tirumotecan plus Pembrolizumab in PD-L1-Negative Advanced NSCLC.

BACKGROUND Pembrolizumab plus chemotherapy with a platinum-based agent and pemetrexed is a widely used standard first-line treatment option for patients with programmed death ligand 1 (PD-L1)-negative advanced nonsquamous non-small-cell lung cancer (NSCLC) without targetable genomic alterations, but outcomes remain sub...

Fei Zhou, Xiang-Jiao Meng, Qing-Qing Ding et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.